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Abstract 
Background  Observational studies have shown associations between nutritional status 
and cognition in later life but evidence from intervention studies is unclear. This study 
systematically reviewed the evidence on the effect of nutrient supplementation on 
cognitive function in people ≥ 65y. 
Methods Databases including MEDLINE and EMBASE were searched up to 1 
September 2006. Randomised controlled trials using at least one kind of vitamin, 
mineral or omega-3 fatty acid, evaluating standardised neuropsychological test(s) were 
included. There were no restrictions on participants’ baseline nutritional status or 
cognitive function. Quality assessment and data abstraction was conducted by one 
author and checked by another.  
Results  Of 4229 articles retrieved, 22 trials (3442 participants) were identified. 
Many were small, short duration and poor methodology. Only 16 out of 122 cognitive 
tests were significantly different between groups. Meta-analysis showed no significant 
effect of taking B vitamins or antioxidant vitamins on global cognitive function. There 
was insufficient evidence to evaluate the effect of omega-3 fatty acids on any cognitive 
domains. 
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Conclusion  There was little evidence of a beneficial effect from taking B vitamins or 
antioxidant supplements on global cognitive function in later life. Larger scale 
randomised controlled trials of longer duration in selected age groups are needed.   
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Cognitive function declines with age. It ranges from mild cognitive decline to dementia 
which is one of the most disabling and burdensome health conditions worldwide. It is 
estimated that 24 million people worldwide had dementia in 2001 and the number of 
people affected will double every 20 years by 2040 (Ferri et al., 2005). About 60% of 
dementia is due to Alzheimer’s disease which is characterised by progressive cognitive 
deterioration, together with declining activities of daily living and behavioural changes 
(Ferri et al., 2005). Alzheimer’s disease is a neurodegenerative disease complicated by 
inflammatory reaction in the brain (Pasinetti 1996).  
More than 15% of community living people aged 65 years old and over are 
deficient in one or more micronutrient, rising to over 40% of those living in institutions 
(Finch et al., 1998). More than 20% of older people in the UK are regular dietary 
supplement users (Finch et al., 1998), with vitamins, minerals and fatty acids being the 
most frequently self-administered supplements. However, large randomised controlled 
trials (RCTs) and systematic reviews have found little positive effect of micronutrients 
and fatty acids supplements on cancer (Blot, 1997; Bjelakovic et al., 2004), 
cardiovascular disease (Eidelman et al., 2004; Hooper et al., 2004), infection (Avenell 
et al., 2005a; El-Kadiki & Sutton, 2005), or fracture, except for very high risk people in 
nursing homes (Avenell et al., 2005b).  The hypothesis of this study was that single or 
combinations of vitamin, mineral and/or fatty acid supplements, as might be purchased 
over the counter by older people, might help maintain cognitive function since 
micronutrients and fatty acids are essential for proper neurological function. B vitamins 
and folate are methyl donors in the synthesis of neurotransmitters, neuron membrane 
phospholipids and DNA (Bottiglieri, 1996). Lack of B vitamins can also cause the 
accumulation of homocysteine, which may damage vascular structure and neurons 
(Hankey & Eikelboom, 1999). Antioxidant micronutrients such as vitamin C, E and zinc 
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may protect the nervous system from free-radical-induced oxidative damage (Vatassery, 
1998). Omega-3 fatty acids play important roles in neuronal growth, development of 
synaptic processing for neural cell interaction, and expression of genes regulating cell 
differentiation and growth (Uauy & Dangour, 2007).  
Previous Cochrane reviewers have focused on supplementation with vitamins B1 
(Rodriguez-Martin et al., 2003) and E (Tabet et al., 2000) in people with Alzheimer’s 
disease. Insufficient evidence was found to assess benefit. This was also the case in 
previous Cochrane reviews of vitamin B6 (Malouf & Grimley Evans, 2003), folic acid 
(Malouf et al., 2003), and omega-3 fatty acids (Lim et al., 2006) in people with or 
without cognitive impairment; and vitamin B12 with or without folic acid in people 
having low blood concentrations of vitamin B12 (Malouf & Areosa, 2003). The present 
review explored the effect of not only single vitamins, minerals, and omega-3 fatty 
acids on cognitive function but also their combination as might be purchased over the 
counter. As it was unclear how baseline cognitive ability and nutritional status may 
have an impact on any supplementation effect, the present review included older people 
with any level of cognitive ability or nutritional status. Subgroup analysis was 
predefined to identify the group of people that may be more sensitive to a certain type of 
nutrient supplementation, where data were available. 
 
Methods:  
Search strategy 
Seven electronic databases, including MEDLINE, EMBASE, Cochrane Central Register 
of Controlled Trials, and CAB abstracts up to 1 September 2006 were searched for 
RCTs on the effect of diet supplementation on cognitive function in people ≥65y. 
Medical subject headings and text words related to dietary supplements, vitamins, 
minerals, fatty acids, cognition, ageing, and RCTs were used. Terms were adapted for 
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BIOSIS, AGRICOLA, PsycINFO up to 1 September 2006, and for official websites for 
registered randomised trials in the UK (National Research Register, 2006), USA (The 
U.S. National Institutes of Health Clinical Trials Database, 2006), Europe (European 
Union Community Research and Development Databases, 2006) and worldwide 
(International Standard Randomized Controlled Trial, 2006). Further details are 
available from the authors. The titles and abstracts obtained were screened for relevant 
articles. Full texts of the relevant articles were checked for inclusion criteria. Secondary 
references were checked. Twenty pharmaceutical companies worldwide were contacted 
for unidentified trials. No language limits were imposed on the searches. 
 
Study selection criteria 
Trials were included if they met the following criteria, otherwise they were excluded:  
(1) Standardised neuropsychological test(s) were used to measure cognitive changes, for 
example, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) for 
measuring global cognitive function (Rosen et al., 1984) and the Rey Auditory Verbal 
Learning Test (AVLT) for measuring memory and learning (Rey, 1964). 
(2) The supplement contained at least one kind of vitamin, mineral or omega-3 fatty 
acid 
(4) There was evidence of random allocation and evidence of having a control or 
placebo group for comparison 
(5) All participants were 65 years old or older 
 
To increase the generalisability of the results, no restrictions were placed on study 
setting (community, psychiatric clinic, or hospital), or the treatment received in the 
control group (no treatment, placebo, or concomitant routine care) (Gotzshe, 2000). 
There were also no restrictions on participants’ baseline nutritional status or cognitive 
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function. Participants with depression were included because there is evidence that 87% 
of people with Alzheimer’s disease and 19-27% of people with cardiovascular disease 
associated dementia also have depression (Fischer et al., 1990). The supplements could 
be taken by any route with any dose or duration. Trials with any degree of blinding were 
included.  
 
Types of outcomes 
Primary outcomes were changes in cognitive performance. The assessments were 
categorised into eleven groups: global cognition, attention and concentration, short-term 
memory, long-term memory, recognition, processing speed, executive function, verbal 
ability, verbal fluency, and naming. For example, digit span forward and immediate 
recall from Rey’s Adult Verbal Learning Task were both grouped into short-term 
memory. Secondary outcomes were changes in nutrient status, homocysteine 
concentrations, and adverse events.  
 
Data abstraction and quality assessment of RCTs  
One author abstracted the data using an in-house data extraction form, and another 
checked the accuracy. A 10-item quality appraisal form based on that used in a 
Cochrane review (Avenell & Handoll, 2005) was used to assess the methodological 
quality of each included trial. The 10 items include the concealment of randomisation, 
blinding of assessment of outcomes, intention to treat analysis, the specification of 
inclusion and exclusion criteria, definition of the intervention, the overall duration of 
the intervention and length of follow up. Each item was given 0-2 (highest) scores 
according to quality.  
 
Statistics  
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All the quantitative data were continuous data. Cognitive tests reported by the included 
trials were grouped into 11 cognitive domains.  
For cognitive domains that reported sufficient data (at least three trials reporting 
mean change and standard deviation, SD), the Cochrane Collaboration’s Review 
Manager computer program RevMan (v.4.2, 2002) was used. According to the 
biochemical mechanisms, pre-specified subgroup meta-analysis was used to investigate 
the effect of B vitamins, antioxidant vitamins, omega-3 fatty acids, and combination of 
vitamins and minerals. The number of participants in the meta-analysis was the number 
with both initial and final measurements available, i.e. drop-outs and deaths were 
excluded by the investigators. Weighted mean difference was used for cognitive 
domains that tested by the same cognitive test; standardised mean difference was used 
for domains that tested by different cognitive tests since different scoring methods were 
used. A random effects model was used because of the diverse interventions (Higgins et 
al., 2003). Pre-specified sensitivity analyses were not conducted for large trials or 
longer duration trials since few trials had more than 30 participants and duration longer 
than six months. 
Some trials presented multiple tests for the same cognitive domain. To avoid 
multiple results from one trial for one cognitive domain being entered into one meta-
analysis, only the results of the first test for each domain that appeared in the report was 
included in the meta-analysis. The first test reported was chosen to avoid bias in the 
results. For multi-arm trials that used the same control group (Bryan et al., 2002; Seal et 
al., 2002), to avoid multiple entry of the results from placebo group, the results from 
supplement groups were combined. 
A narrative report is provided for other outcomes such as change in nutrient 
concentrations, homocysteine concentrations and adverse events. 
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Authors were contacted for unpublished MMSE data. The MMSE is a widely used tool 
to screen for cognitive impairment and dementia. MMSE score ranges from 0 to 30. If 
the number of participants in each group was not reported, it was calculated by dividing 
the total number of participants by the number of arms, for example Bryan et al. (2000). 
If the mean change and SD were unavailable but the final mean was available, the mean 
change was calculated by subtraction of the baseline mean by the final mean. Imputed 
values were calculated for the missing SDs based on a method provided by Avenell et 
al. (2004). SD of mean change was available for four trials (Kowk et al., 1998; Seal et 
al., 2002; Clarke et al., 2003; Petersen et al., 2005). SD of mean change of the other 
three trials (Nolan et al., 1991; Sano et al., 1997; McMahon et al., 2006) was imputed. 
The imputed SD was calculated from a formula derived from a linear regression of SDs 
on the mean change from trials that reported both results. The imputed SDs were: 
SD of MMSE  = 4.673 + (1.466 × mean change) 
 
Imputed SDs for tests assessing other cognitive domains were not possible, as the 
number of trials that reported the SDs of mean change was too small (less than half of 
the trials that reported corresponding outcomes) to meet the assumption of linear 
regression. Hence meta-analyses were only conducted for global cognitive function 
tested by MMSE.  
 
Results 
A total of 4229 articles were found on initial searching of the electronic databases. No 
pharmaceutical companies replied. Thirty one full text papers were checked for 
inclusion (Figure 1). Twenty two completed trials (in 22 papers) including thirty three 
interventions were included in the review. Twenty five interventions used B vitamin(s) 
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as supplements (Table 1), four used antioxidant vitamin(s) (Table 2), one used 
docosahexanoic acid (DHA) (Table 3), and three used combined vitamins and minerals 
(Table 4). Four trials on B vitamins were multiple interventions (Bryan et al., 2002; 
Seal et al., 2002; Scott et al., 2005; Eussen et al., 2006). One trial on vitamin B12 and 
vitamin E used a 222 factorial design (Clarke et al., 2003). All the trials were 
conducted in developed countries, and academic institutes or national organizations 
supported all of them. None reported pharmaceutical company funding.  
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[Insert table 1, 2, 3, 4] 
 
Four trials reported random allocation which did not appear to disclose assignment 
(Bryan et al., 2002; Clarke et al., 2003; Scott et al., 2005; McNeill et al., 2007)( Table 
5). Only one trial mentioned that the outcome assessment was blinded (Clarke et al., 
2003). Nineteen trials had more than 30 participants. The trial which used a crossover 
design (Meador et al., 1993) involved 29 participants.  
[Insert table 5] 
 
Another seven trials are on-going (Aisen, 2006; Dangour, 2006; Runyons, 2006; 
Smith, 2006; The MEMO study, 2006; van Uffelen et al., 2006; Walker & Christensen, 
2006). One study of combined vitamins and minerals (Chandra, 2001), which has 
subsequently been withdrawn (Meguid, 2005), was not included.  
 
Baseline characteristics of participants 
The 22 included trials involved 3442 participants (male 1490, female 1759, unknown 
gender 193). The sample sizes ranged from 11 to 276.  
From the 15 trials on B vitamins with 25 different interventions (Table 1), the 
participants of six trials were from the community (Deijen et al., 1992; De La Fourniere 
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et al., 1997; Bryan et al., 2002; Sommer et al., 2003; Lewerin et al., 2005; McMahon et 
al., 2006) and the other participants were from hospitals or clinics, most of whom had 
dementia. Nine trials reported the participants’ baseline blood level of B vitamins 
(Deijen et al., 1992; Passeri et al., 1993; De La Fourniere et al., 1997; Fioravani et al., 
1997; Kwok et al., 1998; Seal et al., 2002; Sommer et al., 2003; Eussen et al., 2006; 
McMahon et al., 2006). Participants in five trials had low blood levels of vitamin B12 
(De La Fourniere et al., 1997; Kwok et al., 1998; Seal et al., 2002; Eussen et al., 2006) 
or folate (Fioravanti et al., 1997). The cut-off used for low vitamin B12 status was 
different across trials. De La Founiere et al. (1997) used serum vitamin B12 less than 
240 pg/ml, Eussen et al. (2006) used 100-300 pmol/l), Kwok et al. (1998) used less than 
120 pmol/l and Seal et al. (2002) used 100-150 pmol/l. The cut-off used for low folate 
status was serum folate < 3ng/ml (Fioravanti et al., 1997). Ten trials reported that 
participants had baseline global cognitive decline which ranged from mild cognitive 
decline through to severe dementia (Nolan 1991 et al.; Meador et al., 1993; De La 
Fourniere et al., 1997; Fioravanti et al., 1997; Kwok et al., 1998; Seal et al., 2002; 
Clarke et al., 2003; Sommer et al., 2003; Scott et al., 2005; Eussen et al., 2006). 
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 For the four trials on antioxidant vitamins (Table 2), the participants of two trials 
were from the community (Smith et al., 1999; Petersen et al., 2005) and the others were 
from hospitals (Sano et al., 1997; Clarke et al., 2003). Three trials reported the baseline 
cognitive function as having various degrees of cognitive decline (Sano et al., 1997; 
Clarke et al., 2003; Petersen et al., 2005). None of these trials reported baseline 
nutritional status. 
 The participants from the DHA trial were from a home for older people with 
cardiovascular disease associated dementia (Terano et al., 1999, Table 3). Their 
nutritional status was not reported. 
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 For the three trials where combinations of vitamins and minerals were used 
(Table 4), participants from two trials were healthy volunteers from the community 
(Cockle et al., 2000; McNeill et al., 2007) and the others were from a health centre (De 
Jong et al., 2001). None reported baseline nutritional status or cognitive function. The 
MAVIS trial (McNeill et al., 2007) assessed nutritional risk using a simple 
questionnaire, but did not measure intake or blood levels. 
 
Supplements used in the trials 
The nutrient composition, administration route, dose and duration of the 
supplementation varied widely across trials. Two interventions used vitamin B1 (Nolan 
et al., 1991; Meador et al., 1993), one used riboflavin (Scott et al., 2005), three used 
vitamin B6 (Deijen et al., 1992; Bryan et al., 2002; Scot et al., 2005), five used vitamin 
B12 (De La Fourniere et al., 1997; Kwok et al., 1998; Bryan et al., 2002; Seal et al., 
2002; Eussen et al., 2006), four used folic acid (Passeri et al., 1993; Fioravanti et al., 
1997; Bryan et al., 2002; Sommer et al., 2003), five used combinations of B vitamins 
(Clarke et al., 2003; Lewerin et al., 2005; Scott et al., 2005; Eussen et al., 2006; 
McMahon et al., 2006), two used vitamin E alone (Sano et al., 1997; Petersen et al., 
2005), two used combinations of antioxidant vitamins (Smith et al., 1999; Clarke et al., 
2003), one used DHA (Terano et al., 1999), and three used low dose combinations of 
vitamins and minerals (Cockle et al., 2000; De Jong et al., 2001; McNeill et al., 2007).  
All supplements in the included trials were administered orally daily except two 
trials that used intramuscular injection of vitamin B12 (De La Fourniere et al., 1997; 
Kwok et al., 1998). The doses of nutrients were compared with the UK Reference 
Nutrient Intake (RNI) (Department of Health, 1991). Pharmacological doses of vitamin 
B12 (more than 300 times RNI) were used in Lewerin et al. (2005) and Clarke et al. 
(2003) and pharmacological doses of vitamin B1 (more than 3000 times RNI) were used 
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in Meador et al. (1993) and Nolan et al. (1991). Nine interventions were for more than 
six months (four of B vitamins, three of antioxidant vitamins, one DHA and two of 
combinations of vitamin and minerals). Two had no interventions in control groups 
(Kwok et al., 1998; Terano et al., 1999).  One used regular products without vitamins 
and minerals in the control group (same energy content as the intervention group) (De 
Jong et al., 2001). The other trials all used a placebo as the control. 
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Cognitive assessment 
122 different psychological assessments were used to measure the cognitive changes but 
only twenty three were used in more than one trial. Scores of sixteen assessments 
showed significant differences between supplement and control groups with ten 
favouring the supplements (Table 6). Five of these ten assessments were from the small 
trial by Fioravanti et al. (1997), where 15mg folic acid was given daily to people with 
mild to moderate cognitive decline for 60 days.  
In short-term memory, two test results for B vitamins which favoured the 
treatment group were statistically significant. One of these was a small trial which used 
15mg folic acid daily for people with mild to moderate cognitive decline for 60 days 
(Fioravanti et al., 1997). The other used 50mg folic acid daily for people with mild to 
moderate dementia for eight weeks (Passeri et al., 1993).  
There was no other consistent pattern in the significant results in respect of the 
kind of nutrient used, baseline nutritional status or cognitive function.  
[Insert table 6] 
 
Sufficient data were available for the meta-analysis of global cognitive function 
measured by MMSE and short-term memory measured by a variety of tests.  
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MMSE was used in eight trials with nine interventions with five of B vitamins, 
three of antioxidant vitamins and one of DHA. Subgroup meta-analysis was therefore 
not possible for DHA. In the seven trials, all the participants were cognitively impaired 
except the ones in McMahon et al’s trial (2006). In the subgroup analysis by kind of 
nutrient (Figure 2), the heterogeneity of effects in both subgroups was zero. B vitamins 
had a non-significant negative effect (weighted mean difference -0.09, 95% CI -0.97 to 
0.78, p=0.84) and antioxidants had a non-significant positive effect (weighted mean 
difference 0.58, 95% CI -0.17 to 1.33, p=0.13). The results were similar whether trials 
with assumed SDs were included or excluded. 
Sufficient data were available (Kwok et al., 1998; Seal et al., 2002) for the 
meta-analysis of MMSE in participants with low baseline vitamin B12 status. Vitamin 
B12 had a non-significant negative effect in these people with effect size -0.52 units of 
MMSE score (95% CI -1.67 to 0.62, p=0.13).  
 
Changes of nutrients status and homocysteine status 
Eight trials measured changes in nutritional and homocysteine status. In the trials where 
supplements contained vitamin B12 ranging from 1.25g to 3mg, vitamin B12 status 
significantly increased and homocysteine also significantly decreased (De Jong et al., 
2001; Seal et al., 2002; Clarke et al., 2003; Scott et al., 2005; Eussen et al., 2006; 
McMahon et al., 2006). Red blood cell folate and serum/plasma folate (Passeri et al., 
1993; De Jong et al., 2001; Seal et al., 2002), vitamin B6 (De Jong et al., 2001), beta-
carotene, vitamin C, E (Smith et al., 1999) were also increased significantly by 
supplements with corresponding nutrients. However, in the same trials no significant 
improvements in cognitive performance were observed. 
 
Adverse effects 
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Two trials reported adverse events from using vitamin E (Sano et al., 1997; Petersen et 
al., 2005) including abnormal dreams, arthritis, bronchitis, cataract extraction, diarrhea, 
loose stools, insomnia, muscle cramps, nausea, vomiting; dental event, falls and 
syncope. None found a significant increase in adverse events. Data on compliance were 
rarely presented.  
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Discussion 
The results of the present review suggest that B vitamins and antioxidant vitamins used 
in the trials were unlikely to have clinically important effects on global cognitive 
function. Participants with cognitive impairment or dementia with or without low 
vitamin B status did not appear to benefit from B vitamin supplementation. There was 
insufficient evidence to evaluate the effect of omega-3 fatty acids or the effect of taking 
supplements on any specific cognitive domains. These findings are consistent with an 
earlier review of seven trials of vitamins and minerals (Manders et al., 2004). 
 
Possible reasons for the lack of positive effects from supplementation 
The lack of beneficial effect of supplementation is unlikely to be due to inadequate 
dosage. The lack of effect might be due to insufficient duration of supplementation and 
inadequately powered studies. The metabolic changes that contribute to cognitive 
decline may start from young adulthood (Richards et al., 2004); and could be difficult to 
reverse in later life. It is also possible that particular stages of aging are more sensitive 
to supplements, such as those people who are very old. In the MAVIS trial there was no 
effect of multiple micronutrient supplementation in all participants who were 65 years 
old or over but weak evidence for a beneficial effect in those 75 years old or over 
(McNeill et al., 2007).  
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Strength and limitations of the present review 
This study included a wide range of populations with all levels of cognitive status and 
nutritional status, and studied the effects from individual nutrients and combinations. 
People with depression were also included because the prevalence of depression is very 
high in cognitively impaired or demented people. Participants’ baseline nutritional 
status and cognitive status were often not defined or defined by inconsistent criteria.  
Grouping of neuropsychological tests was difficult as some tests assessed more 
than one cognitive domain. For example, the tests of higher cognitive function such as 
executive function also require attention, concentration, or short-term memory.  
‘Case available analysis’ in stead of ‘intention to treat’ was used in this study as 
a larger proportion of trials provided these data. Little heterogeneity of effects measured 
by MMSE in meta-analysis suggests consistency amongst the trials.   
 
Excluded trials, on going RCTs  
Two RCTs were excluded because not all the participants were over 65 years old and 
neither trial found significant effects from taking antioxidant vitamin supplements 
(Heart Protection Study Collaborative Group, 2002) or vitamin B12 supplements (Hvas 
et al., 2004) on global cognitive function. The other seven RCTs were excluded because 
vitamin C (Parnetti et al., 1992; Thomas et al., 2001; Carlsson et al., 2002) or 
niacinamide (Blass et al., 1988) was used as placebo, the outcome measurements were 
not standardised (Yehuda et al., 1996), baseline cognitive abilities were not measured 
(Yaffe et al., 2004) or supplements contained energy but the placebo did not (Wouters-
Wesseling et al, 2005). 
Seven ongoing RCTs were identified, four trials of B vitamins (Aisen, 2006; 
Smith, 2006; van Uffelen et al., 2006, Walker & Christensen, 2006), two trials using 
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omega-3 long chain polyunsaturated fatty acids (Dangour, 2006; The MEMO study, 
2006), and one trial using vitamin E and/or selenium (Runyons, 2006).  
 
Further research 
 The methodological quality of the included trials was generally low and sample 
sizes of most trials were small. Well designed larger scale trials are therefore needed.   
It may be worth investigating supplements made of naturally occurring forms of 
nutrients because the synthetic ones, as found in most supplement products, may have 
less effect (Yeum et al., 1995; Toba et al., 1997).  
The results from two double-blind placebo controlled RCTs suggest very high 
dose folic acid might have significant positive effects on short-term memory in people 
at an early stage of cognitive impairment (Passeri et al., 1993; Fioravanti et al., 1997). 
This is supported by the results of a very recently reported three-year RCT in which 
800μg folic acid was given orally daily to 818 people with elevated plasma 
homocysteine (13 -26 μmol/L) aged 50-70 years (Durga et al., 2007). This trial was 
outside the timescale for our review. More long-term large trials are needed to confirm 
the effects.  
A separate article on Smith et al’s RCT (1999) reported that a subgroup of their 
participants who had both low baseline vitamin C status and low mood and cognition 
were more likely to derive benefits from the increased vitamin C (Smith et al., 1999), so 
further studies to investigate the response in malnourished subgroups may be justified.  
In addition, almost all participants in trials averaged 70 to 80 years old, so it may 
also be worth investigating cognitive changes in younger adults such as 55-70 years old 
or very old adults who are more than 80 years old.  
 
Conclusion  
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The majority of trials did not find statistically significant beneficial effects from taking 
supplements on later life cognitive function in spite of significant increases in blood 
vitamin B12 and folate status, or significant decreases in homocysteine levels. There 
were too few trials to evaluate the effect of taking omega-3 fatty acids. Larger scale 
RCTs with longer duration in selected age groups are needed.   
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Table 1. Characteristics of included trials: Vitamin Bs – B1, Riboflavin, B6, B12, folic acid alone or combined 
 
Study Participants Intervention Outcomes 
Nolan 1991 Setting: Outpatients from Geriatric Evaluation Services of a Rehabilitation 
Centre, USA. 
Sex: 5M, 10F. 
Age: mean years: 76.3. 
Mental status: DAT probable or possible.  
MMSE: mean (SD): (a) 16.6 (5.73), (b) 16.0 (5.7). 
 
(a) Vitamin B1 3g orally daily for 1 year 
(b) Double-blind placebo made from lactose daily for 1 year. 
Allocated: (a) 8, (b) 7 
% Dropout: (a) 37.5%, (b) 28.6% at 1 year. 
 
Follow up: 1 year 
Outcomes: CERAD battery: verbal fluency (categories), short version of the 
Boston naming test, MMSE, constructional praxis test; in addition, 10 item word 
list learning test, and tests of delayed recall and recognition based on the same 
10 word list; adverse events. 
 
Deijen 1992 Setting : community healthy volunteers, Netherlands. 
Sex: 82M 
Age: mean (SD) years: (a) 73 (3), (b) 73 (3). 
Nutrient status: 13 marginal vitamin B6 deficiency, (a) 4, (b) 9. 
IQ > 80, mean (SD) : (a) 109 (11), (b) 111 (10). 
 
(a) Vitamin B6 20mg orally daily for 12 weeks. 
(b) Double-blind placebo for 12 weeks. 
Allocation: (a) 41, (b) 41. 
% Dropout: (a) 7.3%, (b) 7.3%. 
Follow up: 12 weeks 
Outcomes: Sperling whole report task, associated learning task, associated 
recognition task, visual memory task, cognitrone, Vienna determination unit. 
 
Meador 1993 Setting: patient, living with caretaker who paid particular attention to 
nutrient intake, USA. 
Sex: 5M, 13F. 
Age: mean years: 71. 
Mental status: DAT probable 
MMSE: mean (SD): 18 (7).  
 
Cross-over designed. 
(a) Vitamin B1 3g orally daily for 1 month, then placebo for 1 month. 
(b) Double-blind placebo made from lactose orally daily for 1 month, then 
vitamin B1 for 1 month. 
Allocated: (a) 9, (b) 9. 
 
 
Follow up: 2 months 
Outcomes: ADAS-cog, MMSE, adverse events. 
  
 
Passeri 1993 
 
Setting: 6 Geriatric Centres, Italy. 
Sex: 43M, 53F. 
Age: range: (a) 65-92, (b) 65-94. 
Nutrient status: normal folate status: RBC folate: 175-700ng/ml 
Mental status: mild to moderate dementia, 73 Alzheimer’s type, 23 multi-
infarction type, with depression 
 
(a) (b) 7 days wash-out period, then 2 weeks placebo run-in. 
(a) 5’-MTHF 50mg orally daily for 8 weeks. 
(b) Double-blind Trazodone (atypical antidepressant) 100mg controlled for 8 
weeks. 
(a) (b) 4 weeks drug free follow up 
Allocation: (a) 47, (b) 49. 
% Dropout: (a) 0%, (b) 0%. 
 
Follow up: 12 weeks. 
Outcomes: RVM test: immediate and delayed recall, RBC folate status, 
depression tested by HDRS, advert events. 
De La 
Fourniere 1997 
 
Setting: community dwelling inpatient, France.  
Sex: 3M, 8F. 
Age: mean (range): 84 (78, 89)  
Nutrient status: serum B12 < 240 pg/ml, normal folate 
Mental status: Moderate severity AD, MMSE 11-23 
(a) Vitamin B12 1000mg intramuscular injection daily during 5 days, then once 
monthly for 5 months. 
(b) Double-blind placebo for 5 months. 
Allocation: (a) 6, (b) 5. 
Follow up: 5 months. 
Outcomes: ADAS-Cog. 
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Study Participants Intervention Outcomes 
Fioravanti 
1997  
Setting: volunteers who had complains in loosing memory, Italy. 
Sex: 5M, 25F. 
Age: mean (SD): (a) 80.25 (5.78), (b) 80.21 (5.45). 
Nutrient status: Serum folate < 3ng/ml. 
Mental status: very mild to moderate severity of cognitive decline, no 
dementia. 
 
(a) Folic acid 15mg orally daily for 60 days. 
(b)  Placebo for 60 days 
Allocation: (a) 16, (b) 14. 
 
Follow up: 60 days. 
Outcomes: Randt memory test. 
 
Kwok 1998 Setting: hospital medical outpatient clinics or wards, Hong Kong.  
Sex: 1M, 51F. 
Age: mean (SD) years: (a) 76.6 (6.8), (b) 77.4 (6.4).  
Nutrient status: majority vegetarians, serum B12 <120 pmol/l. 
Mental status: 10 dementia, (a) 7, (b) 3. 
MMSE: mean (SD): (a) 22.2 (4.7), (b) 23.8 (4.7). 
 
(a) Vitamin B12 1mg intra muscular injection 3 doses in first week, then 1 dose 
weekly for three weeks, then 1 dose monthly for 2-5 m. 
(b) No intervention for 2-5 m. 
Allocation: (a) 24, (b) 28. 
% Dropout: (a) 4.2%, (b) 3.6%.  
 
Follow up: 3-6 months 
Outcomes: MMSE, WAIS revised: digit span, similarities, block design; 
Wechsler memory scale revised: logical memory, visual reproduction; Luria-
Nebraska neuropsychological battery: motor function scale; IQ: verbal, 
performance. 
 
Bryan 2002 Setting: community healthy volunteers, Australia. 
Sex: 75F. 
Age: mean years: 74.08 (5.75). 
Nutrient status: sufficient vitamin B consumption (measured by food 
frequency questionnaire). 
 
(a) Vitamin B6 75mg orally daily for 35d. 
(b) Vitamin B12 15μg orally daily for 35d. 
(c) Folate 750μg orally daily for 35d. 
(d) Double-blind placebo (Ca, Mg, etc) for 35d. 
 
Follow up: 35d 
Outcomes: boxes test, WAIS-III: digit-symbol coding, symbol search, digit span 
backward, letter-number sequencing, vocabulary; spot the word, RAVLT, 
Stroop test, uses for common objects, the trail making test, verbal fluency 
(comprising initial letter & excluded letter); CESD. 
 
Seal 2002 Setting: two geriatric hospitals, Australia. 
Sex: 14M, 17F. 
Age: mean years: (a) 84.9, (b) (82.0), (c) (77.6). 
Nutrient status: Serum vitamin B12 100-150 pmol/l. 
Mental status: 1/3 dementia 
MMSE: mean (SD): (a) 15.4 (7.8), (b) 19.6 (6.3), (c) 19.7 (5.3). 
 
(a) Vitamin B12 10g orally daily for 4 weeks. 
(b) Vitamin B12 50μg orally daily for 4 weeks. 
(c) Double-blind placebo for 4 weeks. 
Allocation: (a) 10, (b) 10, (c) 11 
% Dropout: (a) 0%, (b) 10%, (c) 27.3%. 
 
Follow up: 4 weeks. 
Outcomes: MMSE, serum vitamin B12, plasma homocysteine, blood folate 
status. 
 
 
 
Clarke 2003 
 
Setting: recruited from hospital records, general practice registers, 
advertisement, UK. 
Age: mean: 75y 
Mental status: Dementia or mild cognitive impairment. 
MMSE: mean (SD): (a) 20.9 (3.9), (b) 20.1 (3.9) 
 
(a) (b) 4 weeks placebo-controlled run-in. 
(a) Vitamin B12 1mg and folic acid 2mg orally daily for 12 weeks. 
(b) Double-blind placebo for 12 weeks. 
Allocation: (a) 74, (b) 75. 
 
Follow up: 12 weeks. 
Outcomes: MMSE, TICS-M, plasma homocysteine. 
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Sommer 2003  Setting: community volunteer, USA. 
Sex: 4M, 3F (completed study) 
Age: mean: (a) 76.3, (b) 77.3. 
Nutrient status: serum folate 2-5mcg/l, RBC folate 127-452mcg/l, 
B12>200ng/l.  
Mental status: dementia of various types and severity. 
 
(a) Folic acid 20mg orally daily for 10 weeks. 
(b) Double blind placebo for 10 weeks. 
Allocation: (a) 6, (b) 5. 
% Dropout: (a) 17%, (b) 60% 
Follow up: 10 weeks. 
Outcomes: WAIS-R: vocabulary, similarities; Boston naming test, controlled 
oral world association test, Wechsler memory scale: logic memory, associate 
learning; Benton visual retention test, trail making test: trail A, B; finger tapping 
test, adverse events. 
 
 
Lewerin 2005 
 
Setting: community, Sweden. 
Sex: 78M, 117 F 
Age: mean (SD): (a) 75.7 (4.7), (b) 75.6 (4.0). 
 
(a) Vitamin B6 3mg, vitamin B12 500μg, and folic acid 800μg, orally daily for 4 
months. 
(b) Double-blind placebo for 4 months. 
Allocation: (a) 126, (b) 69. 
% Dropout: (a) 13%, (b) 16%. 
 
Follow up: 4 months. 
Outcomes: digit span backward/forward, identical forms, Wechsler memory 
scales: visual reproduction; synonyms, block design, digit symbol, Thurstone’s 
picture memory test, figure classification.  
Scott 2005 Setting: 2-centre, hospital based, UK. 
Age: mean (SD): (a) 72.9 (6.0), (b) 74.6 (5.3), (c) 74.7 (6.1), (d) 76.5 (8.0), 
(e) 72.6 (6.4), (f) 74.2 (6.8), (g) 74.0 (6.5), (h) 72.8 (5.4). 
Mental status: mild cognitive impairment 
Physical status: ischemic vascular disease 
(a) (b) (c) (d) (e) (f) (g) (h) 2-4 weeks placebo run in 
(a) Folic acid 2.5mg and vitamin B12 500ug orally daily for 12 weeks. 
(b) Riboflavin 25mg orally daily for 12 weeks. 
(c) Vitamin B6 25mg orally daily for 12 weeks. 
(d) Folic acid 2.5mg, vitamin B12 500ug, and riboflavin 25mg orally daily for 12 
weeks. 
(e) Folic acid 2.5mg, vitamin B12 500ug, and vitamin B6 25mg orally daily for 12 
weeks. 
(f) Riboflavin 25mg and vitamin B6 25mg orally daily for 12 weeks. 
(g) Folic acid 0.5mg, vitamin B12 500ug, riboflavin 25mg, and vitamin B6 25mg 
orally daily for 12 weeks. 
(h) Placebo orally daily for 12 weeks. 
Allocation: (a) 23, (b) 23, (c) 23, (d) 23, (e) 23, (f) 23, (g) 23, (h) 24. 
 
Follow up: 12 weeks. 
Outcomes: letter-digit coding test, telephone interview of cognitive status; 
folate, vitamin B12, riboflavin, vitamin B6, and homocysteine status. 
Eussen 2006 Setting: free-living or care house –living older persons 
Sex: 46M, 149F 
Age: mean (SD): (a) 82 (5), (b) 83 (6), (c) 82 (5) 
Nutrient status: serum vitamin B12 100-300 pmol/l (mild deficiency) 
Mental status: MMSE  19; 14% cognitive impaired (MMSE 19-24) 
 
(a) (b) (c) 2 weeks placebo run-in 
(a) Vitamin B12 1000μg for 24 weeks. 
(b) Vitamin B12 1000μg, folic acid 400μg for 24 weeks. 
(c) Double-blind placebo for 24 weeks. 
Allocation: (a) 64, (b) 66, (c) 65 
% Dropouts: (a) 16%, (b) 23%, (c) 12% 
 
Follow up: 24 weeks. 
Outcome: complex figure of Rey, digit span forward, motor planning, finger 
tapping, trail making test, 15 word learning, digit span backward, stroop test, 
similarities WAIS, Raven’s progressive matrices, word fluency (animals, letter); 
vitamin B12 status. 
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McMahon 
2006 
Setting: community healthy volunteer, New Zealand. 
Sex: 141M, 112F (at 1 year) 
Age: mean (SD): (a) 73.6 (5.8), (b) 73.4 (5.7) 
Nutrient status: plasma homocysteine  13 umol/l 
MMSE: mean (SD): (a) 29.2 (1.0), (b) 29.2 (1.0) 
 
(a) Folate 1000ug, vitamin B12 500μg, and vitamin B6 10mg, orally daily for 2 
years. 
(b) Double-blind placebo for 2 years. 
Allocation: (a) 138, (b) 138 
% Dropout: (a) 10%, (b) 10% at 2 years. 
Follow up: 2 years 
Outcome: MMSE, Rey auditory verbal learning test, paragraph-recall test from 
the Wechsler Memory Scales, controlled oral word association test of the 
multilingual aphasia examination, word fluency (category), trial making test, 
Raven’s progressive matrices; plasma homocysteine, folate, and vitamin B12 
status. 
 
1IU vitamin E, 0.292 mg; AD, Alzheimer’s Disease; ADAS-cog, Cognitive portion of the Alzheimer's Disease Assessment Scale; CERAD, Consortium to establish a registry for Alzheimer’s Disease; CESD, Center for Epidemiological Studies Depression 
Scale; DAT, Dementia Alzheimer’s Type; HDRS, Hamilton Depression Rating Scale; IQ, Intelligence Quotient; MMSE, Mini-Mental State Examination; PLP, pyridoxal –5’-phosphate; RAVLT – Rey-Auditory Verbal Learning Tests; RBC, Red Blood 
Cell; RVM test, Rey's Verbal Memory test; SD, Standard Deviation; TICS-M, Telephone Interview Cognition Scales Modified; WAIS, Wechsler Adult Intelligence Scale;  
 
In the meta-analysis (Figure 2), SD of mean change was available for Kwok et al., 1998, Seal et al., 2002, and Clarke et al., 2003, SD of mean change of Nolan et al., 1991 was imputed. 
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Table 2. Characteristics of included trials: Antioxidant vitamins. 
 
Study Participants Intervention Outcomes 
Sano 1997  Setting: USA. 
Sex: 58M, 111F. 
Age: mean (SD): (a) 73.4 (7.8), (b) 73.5 (8.3). 
Mental status: moderate severity of probable AD 
MMSE: mean (SD): (a) 11.3 (5.7), (b) 13.3 (4.9). 
 
(a) Vitamin E 2000 IU for 2 years. 
(b) Double-blind placebo for 2 years. 
Allocation: (a) 84, (b) 85. 
% Dropout: (a) 5%, (b) 7%. 
Follow up: 2 years. 
Outcomes: MMSE, ADAS- Cog, quality of life: dependence scale, behavior 
rating scale for dementia, institulization, adverse events. 
  
Smith 1999 
 
Setting: volunteers recruited by advertisement, UK. 
Sex: 95M, 110F. 
Age: mean: (a) 66.8, (b) 66.9. 
 
 
(a) (b) 4 weeks placebo run-in 
(a) -carotene 12mg, -tocopherol 400mg and ascorbic acid 500 mg orally daily 
for 12 months. 
(b) Double-blind placebo for 12 months. 
Allocation: (a) 93, (b) 92. 
% Dropout: (a) 2.1%, (b) 16.4%. 
 
Follow up: 12 months. 
Outcomes: Free recall task, Delayed recognition memory task, Logical 
reasoning task, Simple reaction time task, Repeated-digits vigilance task, Focus 
attention task, Categorical search task, plasma ascorbic acid, a-carotene, total b-
carotene, a-tocopherol. 
Clarke 2003 Setting: recruited from hospital records, general practice registers, 
advertisement, England. 
Age: mean: 75y 
Mental status: Dementia or mild cognitive impairment. 
MMSE: mean (SD): (a) 20.2 (3.8), (b) 20.8 (3.9) 
 
(a) (b) 4 weeks placebo-controlled run-in. 
(a) Vitamin C 200mg and E 500mg orally daily for 12 weeks. 
(b)  Double-blind placebo for 12 weeks. 
Allocation: (a) 75, (b) 74. 
 
Follow up: 12 weeks. 
Outcomes: MMSE, TICS-M, plasma homocysteine. 
Petersen, 2005  Setting: community, USA 
Age: mean (SD): (a) 72.8 (7.3), (b) 72.9 (7.6) 
Mental status: amnestic subtype of mild cognitive impairment. 
MMSE: mean (SD): (a) 27.20 (1.9), (b) 27.35 (1.8) 
(a) Vitamin E 1000IU (671mg) daily, then 2000IU after six weeks for 3 years. 
(b) Placebo for 3 years. 
Allocation: (a) 257, (b) 259. 
% Dropout: (a) 28%, (b)26% 
Follow up: 3 years. 
Outcome: MMSE, ADAS-Cog immediate and delayed word recall, global CDR, 
the global deterioration scale, New York University immediate and delayed 
paragraph recall scores, digit span backward, symbol digit modalities test, 
number cancelling test, Boston naming test, verbal fluency (categories), clock 
drawing test, activities of daily living scale. 
 
ADAS-cog, Cognitive portion of the Alzheimer's Disease Assessment Scale; CDR, Scores for the Clinical Dementia Rating; MMSE, Mini-Mental State Examination; SD, Standard Deviation; TICS-M, Telephone Interview Cognition Scales Modified 
 
In the meta-analysis (Figure 2), SD of mean change was available for Clarke et al., 2003 and Petersen et al., 2005, SD of mean change of Sano et al., 1991 was imputed. 
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Table 3. Characteristics of included trials: fatty acids. 
Study Participants Intervention Outcomes 
Terano 1999  Setting: home for the elderly, Japan.  
Age: mean: 83 years. 
Mental status: mild to moderate CVD type of dementia. 
MMSE: mean (SD): (a) 20.1 (5.6), (b) 19.7 (7.1). 
(a) Docosahexaenoic acid (DHA) 0.72g orally daily for 1 year. 
(b) No intervention for 1 year. 
Allocation: (a) 10, (b) 10. 
Follow up: 1 year. 
Outcomes: MMSE, HDRS-R, serum fatty acid composition. 
 
SD, Standard Deviation; MMSE, Mini-Mental State Examination; CVD, Cardiovascular Disease; HDRS-R, Hasegowa’s Dementia Rating Scale.  
 
 
Table 4. Characteristics of included trials: combinations of vitamins and minerals. 
 
Study Participants Intervention Outcomes 
Cockle 2000 
 
Setting: healthy volunteers, Switzerland.  
Sex: 51M, 88F 
Age: mean (SD): (a) 70.7 (5.6), (b) 70.2 (5.4). 
(a) 10 vitamins and minerals 1-10 times RDA, USA, for 24 weeks. 
(b) Double-blind placebo made from rape seed oil for 24 weeks. 
Allocation: (a) (69), (b) (70). 
% Dropout: (a) 4.3%, (b) 12.9 % at 4 weeks. 
 
Follow up: 24 weeks. 
Outcomes:  Critical Flicker Fusion, Choice Reaction Time,  Sternberg Memory 
Scanning Task, World Scan Task, Profile of Mood Status, blood vitamin B1, B2, 
C status (by gender only). 
De Jong 2001 Setting: freeliving frail elderly from health center, BMI<=25 or had recent 
weight loss, the Netherlands. 
Sex: 21M, 45F. 
Age: mean (SD): (a) 78.8 (4.8), (b) 79.0 (7.2). 
 
(a) 13 vitamins and minerals 0.25 – 1 times RDA, Dutch, enriched product plus a 
social program for 17 weeks. 
(b) Regular products (same energy as above) plus a social program for 17 weeks. 
Allocation: (a) (36), (b) (30). 
 
Follow up: 17 weeks. 
Outcomes: Block-transfer Test, Reaction Time test, plasma homocysteine, 
folate, vitamin B6, B12 and RBC folate status. 
 
McNeill 2007 
 
Setting: 6 health centres, 97% living in the community, UK. 
Sex: 479M, 431 F. 
Age: mean (interquartile range): (a) 72 (68, 76), (b) 71 (68, 76). 
 
(a) 16 kinds vitamin and mineral 1-2 times RDA, UK, orally daily for 1 year. 
(b) Double-blind placebo orally daily for 1 year. 
Allocation: (a) (456), (b) (454). 
% Dropout: (a) 12.7%, (b) 17.6%. 
Follow up: 1 year. 
Outcomes: digital span forward, Wechsler Memory Scale : Verbal Fluency 
(initial letter), risk of nurient deficiencies. 
  
RDA, Recommended Daily Allowance; SD, Standard Deviation;  
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Table 5. Quality assessment of included trials 
Study Allocation 
concealment1 
Group 
comparable at 
entry2 
Participants 
blinding3 
Treatment 
provider 
blinding 3 
Assessor  
Blinding3 
Identical care 
programs4 
Withdraws5 Entry criteria 
defined6 
Intervention 
defined6 
Duration7 Total  
score 
Bryan et al., 2002 2 2 2 2 0 0 0 2 2 1 15 
Clarke et al., 2003 2 0 2 2 2 0 1 2 2 1 14 
Cockle et al., 2000 1 2 1 1 0 0 1 2 2 2 14 
de La Fourniere et al., 1997 1 0 1 1 0 0 1 2 2 1 10 
de Jong et al., 2001 1 2 0 0 0 0 1 2 2 1 10 
Deijen et al., 1992 1 2 2 1 0 0 1 2 2 1 13 
Eussen et al., 2006 1 2 2 1 0 0 1 2 2 2 13 
Fioravanti et al., 1997 1 2 1 1 0 0 1 2 2 1 11 
Kwok et al., 1998 0 1 0 0 0 0 0 1 2 1 7 
Lewerin et al., 2005 1 2 1 1 0 0 1 1 2 1 11 
McMahon et al., 2006 1 2 2 1 0 0 1 2 2 2 13 
McNeill et al., 2007 2 2 2 2 0 0 2 2 2 2 18 
Meador et al., 1993 1 2 1 1 0 0 0 2 2 1 11 
Nolan et al., 1991 1 2 2 2 0 0 1 2 2 2 16 
Passeri et al., 1993 1 2 1 1 0 0 1 2 2 1 11 
Petersen et al., 2005 1 2 1 1 0 0 2 2 2 2 13 
Sano et al., 1997 1 2 1 1 0 0 2 2 2 2 13 
Scott et al., 2005 2 2 2 1 0 0 0 2 2 1 12 
Seal et al., 2002 1 2 2 2 0 0 1 2 2 1 15 
Smith et al., 1999 1 2 1 1 0 0 1 2 2 2 13 
Sommer et al., 2003 1 1 1 1 0 0 1 2 1 1 9 
Terano et al., 1999 1 2 0 0 0 1 0 1 1 2 9 
12 = method did not allow disclosure of assignment, 1 = chance of disclosure of assignment or mentioned concealment but not adjusted for, 0 = quasi-randomised 
22 = good comparability of groups, or confounding adjusted for in analysis, 1 = confounding possible, mentioned but not adjusted for, 0 = large potential for confounding, or not discussed 
32 = effective action taken to blind people, 1 = small or moderate chance of unblinding people, 0 = not mentioned (unless double-blind), or not done 
42 = care programes identical, 1 = differences in care programmes but unlikely to influence study outcomes, 0 = not mentioned or differences in care programmes likely to influence study outcomes 
52 = intention to treat analysis based on all cases randomised possible or carried out, 1 = states number and reason for withdrawal but intention to treat analysis not possible, e.g. because outcomes were not measured, 0 = not 
mentioned or not possible 
62 = clearly defined, 1 = inadequately defined, 0 = poorly or not defined 
72 = optimal duration of surveillance (over 6 months), 1 = adequate duration of surveillance (one up to six months), 0 = not defined, or not adequate. 
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Table 6. Changes in cognitive abilities by supplementation compared with control group, with details of studies providing data 
Global cognition Attention and Concentration Recognition
MMSE (Nolan, 1991) → Form perception: cognitrone  (Deijen, 1992) → 10-item word list recognition (Nolan, 1991) → 
ADAS-Cog (Meador, 1993) ↑ Randt memory test: attention efficiency (Fioravanti, 1997) + S Associate recognition task (Deijen, 1992) → 
MMSE (Meador, 1993) ↑ Categoric search task: accuracy (Smith, 1999)  → Delayed recognition memory task (Smith, 1999) → 
ADAS-Cog (De La Fourniere, 1997)  → Focused attention task: accuracy  (Smith, 1999) → Word scan task: male, female (Cockle, 2000) → 
MMSE (Sano, 1997) → Repeated-digits vigillance task: total hit rate  (Smith, 1999) → RAVLT recognition (Bryan, 2002) → 
ADAS-Cog (Sano, 1997) → 15 word learning, recognition (Eussen, 2006) → 
MMSE (Kwok, 1998) → 
Hasegowa’s dementia rating scale (Terano, 1999) +S Long term memory Verbal fluency 
MMSE (Terano, 1999) +S 10-item word list delayed recall (Nolan, 1991) → Verbal fluency: categories (Nolan, 1991) → 
MMSE (Seal, 2002) → Long-term memory storage (Deijen, 1992) ↑ Verbal fluency: excluded letter (Bryan, 2002) → 
MMSE (Clarke, 2003) (B12 + folic acid) → Visual memory task (Deijen, 1992) → Verbal fluency: initial letter (Bryan, 2002) +S  
MMSE (Clarke, 2003) (vitamin C + vitamin E) → Rey’s verbal memory: long-term  (Passeri, 1993) → Controlled oral word association test (Sommer, 2003) → 
TICS-M (Clarke, 2003)  → Randt memory test: delayed recall  (Fioravanti, 1997) +S Verbal fluency: animals, letter (Eussen, 2006) → 
ADAS-Cog (Petersen, 2005)  → RAVLT delayed recall, list 6 (Bryan, 2002) → Controlled oral word association test (McMahon, 2006) → 
Global clinical dementia rating (Petersen, 2005)  → Thurstone’s picture memory task  (Lewerin, 2005) → Verbal fluency: categories (McMahon, 2006) → 
The global deterioration scale (Petersen, 2005) → 15 word learning, delayed recall (Eussen, 2006) → Verbal fluency: initial letter (McNeill, 2007) → 
TICS-M (Scott, 2005) → Complex figure of Rey, delayed recall (Eussen, 2006) → 
MMSE (McMahon, 2006) → RAVLT delayed recall, list 4 (McMahon, 2006) → 
Short term memory Processing speed Verbal ability 
10-item word list learning test (Nolan, 1991) → Randt memory task: encoding (Fioravanti, 1997) +S WAIS-R: similarities (Kwok, 1998) → 
Associate learning task (Deijen, 1992) → Motor function scale: oral motor (Kwok, 1998) -S Spot the word (Bryan, 2002) → 
Sperling whole report task (Deijen, 1992) → Motor function scale: drawing (Kwok, 1998) → WAIS-III: vocabulary (Bryan, 2002) → 
Rey’s verbal memory: short term (Passeri, 1993) +S Motor function scale: fine motor (Kwok, 1998) ↓ WAIS-R: information, vocabulary, similarities (Sommer, 2003) → 
Randt memory test: acquisition and recall (Fioravanti, 1997) +S Motor function scale: kinestesia-based movement (Kwok, 1998) ↓ Synonyms (Lewerin, 2005) -S 
Randt memory test: memory index (Fioravanti, 1997) +S Motor function scale: spatial movement (Kwok, 1998) → WAIS: similarities (McMahon, 2006) → 
Digit span test (Kwok, 1998) → Categoric search task: response time (Smith, 1999) → 
WMS-R: logical memory (Kwok, 1998) → Focused attention task: response time  (Smith, 1999) → Executive function 
WMS-R: visual reproduction (Kwok, 1998) → Repeated-digits vigillance task: total mean reaction time  (Smith, 1999) → Construction praxis test (Nolan, 1991) → 
Free recall task: number of words correctly recalled (Smith, 1999) → Simple reaction time task (Smith, 1999) → Vienna determination unit (Deijen, 1992) → 
Sternberg memory scanning task: male, female  (Cockle, 2000) → Choice reaction time: motor reaction time (Cockle, 2000) → WAIS-R: block design (Kwok, 1998) → 
Digital span backward (Bryan, 2002) → Choice reaction time: recognition reaction time (Cockle, 2000) → Logical reasoning task: number of correctly answered in 3min (Smith, 1999) → 
Letter number sequencing (Bryan, 2002) → Choice reaction time: total reaction time (Cockle, 2000) +S Critical flicker fusion: male, female (Cockle, 2000) → 
RAVLT immediate recall: list 1-5 (Bryan, 2002) → Block transfer test (De Jong, 2001) → Stroop (Bryan, 2002) → 
Benton visual retention test (Sommer, 2003) → Reaction time (De Jong, 2001) → Trial making test: A/B (Bryan, 2002) → 
WMS: Associate learning (Sommer, 2003) -S Boxes test (Bryan, 2002) → Uses of objects (Bryan, 2002) → 
WMS: logical memory (Sommer, 2003) → Digit symbol coding (Bryan, 2002) → Trial making test: A/B (Sommer, 2003) ↓ 
Digit span backward (Eussen, 2006) -S Symbol search (Bryan, 2002) → Block design (Lewerin, 2005) → 
Digital span backward (Lewerin, 2005) → Finger tapping test (Sommer, 2003) → Figure classification (Lewerin, 2005) → 
Digit span forward (Lewerin, 2005) → Digit symbol (Lewerin, 2005) → Motor planning (Eussen, 2006) → 
WMS: visual reproduction (Lewerin, 2005) → Identical forms (Lewerin, 2005) -S Stroop test (Eussen, 2006) → 
15 word learning, immediate recall (Eussen, 2006) → Letter-digit coding test (Scott, 2005) → Trial making test (Eussen, 2006) → 
Complex figure of Rey, immediate recall (Eussen, 2006) → Finger tapping (Eussen, 2006) → Raven’s progressive matrices (McMahon, 2006) → 
Digit span forward (Eussen, 2006) → Motor planning (Eussen, 2006) → Trial making test (McMahon, 2006) -S 
RAVLT: list 1-5 (McMahon, 2006) → 
Wechsler paragraph recall test (McMahon, 2006) → Naming 
Digit span forward (McNeill, 2007) → Short version of Boston naming test (Nolan, 1991) → 
Boston naming test (Sommer, 2003) → 
+S, Effect favoured supplement significantly; -S, Effect favoured control significantly; ↑, Trend favouring supplement; ↓, Trend favouring control; →, Effect was not different between groups; no significant changes were found in Petersen’s study 
(Petersen, 2005).  
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ADAS-cog, Cognitive portion of the Alzheimer's Disease Assessment Scale, with higher scores indicating poorer function; MMSE, Mini-Mental Status Examination, with higher scores indicating better function; RAVLT, Rey-Auditory Verbal 
Learning Tests;.TICS-M, Telephone Interview Cognition Scales Modified, with higher scores indicating better function; WAIS, Wechsler Adult Intelligence Scale; WMS-R, Wechsler Memory Scale-Revised; WMS, Wechsler Memory Scale, with higher 
scores indicating better function. 
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Figure 1 Flow diagram for screening process 
Reports retrieved for more detailed evaluation 
(n=31):  
Excluded reports (n=9): 
Not all the participants aged 65 years or over (n=2) 
Used nutrient as placebo/control (n=4) 
Not used standardised cognitive measurement (n=1) 
Not measured baseline cognitive function (n=1) 
Combined studied nutrient with energy (n=1) 
Excluded reports (n=4198): not meeting inclusion criteria, 
e.g. not a RCT, not all participants aged 65 years or over, 
or no standardised cognitive measurement used. 
RCTs included (n=22)  
Potentially relevant reports identified and screened 
for retrieval (n=4229) 
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